ImmunityBio, Inc. IBRX Interest Expense
Interest Expense at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseOther.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s interest expense?
- ImmunityBio, Inc. (IBRX) reported interest expense of $13.87M in Q1 2026.
- How has ImmunityBio, Inc.'s interest expense changed year-over-year?
- ImmunityBio, Inc.'s interest expense increased by 2.5% year-over-year, from $13.53M to $13.87M.
- What is the long-term trend for ImmunityBio, Inc.'s interest expense?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s interest expense has grown at a 36.5% compound annual growth rate (CAGR), from $14.85M to $51.54M.
- What does interest expense mean?
- The cost of borrowing money, paid to lenders or bondholders.
- How do you interpret interest expense?
- An increase suggests higher debt levels or rising interest rates, which can strain liquidity and profitability.
- How does interest expense compare across companies?
- Depends heavily on the company's capital structure and reliance on debt versus equity financing.